This sale was conducted under a pre-arranged trading plan established in March 2024, in accordance with Rule 10b5-1. Following this transaction, Llewelyn retains ownership of 98,702 shares in the company. While the company isn't currently profitable, InvestingPro data shows analysts expect profitability this year, with 6 analysts recently revising earnings estimates upward. Get access to detailed analysis and 7 additional ProTips for HCAT through InvestingPro's comprehensive research reports. While the company isn't currently profitable, InvestingPro data shows analysts expect profitability this year, with 6 analysts recently revising earnings estimates upward. Get access to detailed analysis and 7 additional ProTips for HCAT through InvestingPro's comprehensive research reports. This sale was conducted under a pre-arranged trading plan established in March 2024, in accordance with Rule 10b5-1. Following this transaction, Llewelyn retains ownership of 98,702 shares in the company.
In other recent news, Health Catalyst (NASDAQ:HCAT) has seen a series of significant developments. The company recently disclosed its third-quarter financial results for 2024, indicating a positive profit and loss execution and a revenue mix shifting back towards software. The leadership team expressed a positive outlook for the company's future growth and provided financial projections for the remainder of 2024 and the full year of 2025.
Piper Sandler showed continued optimism for Health Catalyst, raising the price target on the company's stock to $12.00, up from the previous $11.00. This adjustment comes after incorporating the revised calendar year 2024 guidance provided by Health Catalyst, which expects a robust year-over-year growth of approximately 50% in adjusted EBITDA for calendar year 2025.
In addition, financial services firm Stephens increased the price target for Health Catalyst to $9.00, following the company's third-quarter performance that included a modest EBITDA beat and an affirmation of its full-year 2024 bookings forecast. However, Stephens noted that the outcome of the fourth quarter's bookings could affect projections and is awaiting more clarity on Health Catalyst's growth for fiscal year 2025 before adopting a more constructive stance.
These are just some of the recent developments for Health Catalyst. The company continues to navigate the dynamic healthcare landscape, with stakeholders closely watching its performance against the projections shared in these recent updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.